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corporeal removal of b2-microglobulin.
Background. Dialysis-related amyloidosis (DRA) is a fre-
quent complication of end-stage renal disease (ESRD) that
has been associated with the accumulation of b2-microglobulin
(b2-m). Removal of b2-m results in the loss of important
proteins due to the nonspecific nature of current therapies.
Although whole antibodies can potentially be used to con-
fer specificity to b2-m removal from blood, single-chain vari-
able region (scFv) antibody fragments could potentially offer
several advantages as immunoadsorption ligands due to their
size, genetic definition, ability to be expressed by microbes, and
amenability for in vitro evolution.
Methods. An antihuman b2-m scFv was constructed from the
BBM.1 hybridoma and expressed by a yeast display vector. The
binding affinity of the wild-type scFv fragment was quantified by
flow cytometry analysis. Soluble scFv was expressed by a yeast
secretion vector, purified, and immobilized onto agarose beads.
The binding capacity of the immunoadsorbent was measured by
equilibrating samples with saturating quantities of fluorescent
b2-m in serum.
Results. The displayed scFv possessed a nanomolar affinity
(KD =0.008±0.004 mg-b2-m/L). The immunoadsorbent exhib-
ited an adsorption site density of 0.41 ± 0.01 mg b2-m/mL set-
tled gel. Under saturating conditions, the mass ratio of adsorbed
b2-m to immobilized antibody is 70% greater than any previous
literature report for whole antibodies. Preliminary specificity
experiments suggest that the scFv-based immunoadsorbent is
specific toward human b2-m.
Conclusion. Recombinant DNA technology was successfully
used to engineer an scFv-based immunoadsorbent. Use of im-
mobilized scFvs during hemodialysis may minimize loss of valu-
able proteins and facilitate the removal of macromolecules that
are significantly larger than the molecular weight cut-off of the
membrane.
Key words: dialysis-related amyloidosis, dialysis-associated amyloido-
sis, scFv, immobilized antibodies, yeast display.
Received for publication July 2, 2003
and in revised form August 12, 2003
Accepted for publication August 20, 2003
C© 2004 by the International Society of Nephrology
A frequent complication of end-stage renal disease
(ESRD) is dialysis-related amyloidosis (DRA), a debil-
itating disorder associated with the long-term accumu-
lation of b2-microglobulin (b2-m) [1, 2]. Symptoms are
caused by the formation of amyloid deposits and include
chronic pain, carpal tunnel syndrome, nerve compres-
sions, and cystic bone lesions with associated fractures.
b2-m, the primary constituent of DRA amyloid, is a highly
conserved globular protein (11.8 kD) that is secreted by
all nucleated cells and is specifically removed from the
blood plasma by healthy kidneys. Conventional kidney
function replacement technologies such as hemodialysis,
hemodiafiltration, and peritoneal dialysis are believed to
remove insufficient quantities of b2-m, as they are non-
specific and based on size exclusion [3]. Even so, research
has revealed a correlation between the removal of b2-m
from the circulation and a delay in the occurrence of
symptoms [2, 4, 5]. In recent years, adsorbent matrices
that are based on hydrophobic interaction and size ex-
clusion (Lixelle; Kaneka Co., Ltd., Tokyo, Japan and
Betasorb; Renaltech International LLC, New York,
NY, USA) have been developed for the extracorporeal
removal of b2-m [6, 7]. However, their specificity and/or
affinity for b2-m remains in question, complicating the
evaluation of patient outcome due to their use [8–10].
The ideal technology for the extracorporeal removal
of b2-m should be highly specific, so as to prevent the
significant loss of proteins and other molecules that are
beneficial to the patient. A highly specific b2-m removal
system could also serve as a valuable tool for research. It
could potentially be used to study the therapeutic efficacy
of b2-m clearance independent of the removal of other
molecules that have also been implicated in the pathogen-
esis of DRA, such as inflammatory cytokines [11–13]. The
ideal extracorporeal b2-m removal system should also
possess an affinity for b2-m that is strong enough to bring
the concentration to a level that is well below normal
(1 mg/mL) [14]. This high affinity will serve to maintain
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Fig. 1. Structural comparison of whole antibodies and single-chain
variable region antibody fragments (scFv). Whole antibodies are ap-
proximately 150 kD, while scFv fragments are generally 25 to 30 kD.
The scFv fragment show is assembled in a VH-linker-VL configuration.
a fast apparent rate of adsorption during the available
treatment time-period (by maximizing the concentration
gradient driving the rate of mass transfer). Antibodies are
a logical choice as the active species for a b2-m removal
strategy, as they can be highly specific and posses a high
affinity for their target molecules.
We hypothesize that b2-m can be efficiently removed
from the circulation by immunoadsorptive particles con-
tained within a novel, multicompartment extracorpo-
real device [the Vortex Flow Plasmapheretic Reactor
(VFPR)]. Experiments previously conducted in vitro
with a model immunoadsorbent (BBM.1 monoclonal an-
tibodies [15] immobilized onto agarose gel beads), a
VFPR device prototype, and whole human blood support
the feasibility of the approach [16]. Several characteristics
of the whole BBM.1 antibody-based immunoadsorbent
were found to be quite promising, including its high bind-
ing affinity for b2-m (KD = 0.1 ± 0.1 mg/L) as well as its
ability to be regenerated repeatedly. However, for the
proposed therapy to be successful, a new immunoadsor-
bent with a dramatically increased b2-m adsorption site
density needs to be developed.
As immunoadsorption ligands, single-chain variable
region antibody fragments (scFv) (Fig. 1) offer several
potential advantages over whole, hybridoma-produced
monoclonal antibodies. The transfer of antibody genes
to a nonhybridoma expression vector provides the op-
portunity to eliminate the production of unwanted im-
munoglobulins that may be secreted by the hybridoma
(which has been suspected to be the case for BBM.1)
[16]. ScFv fragments are also smaller in size, which should
theoretically allow for higher densities of accessible ad-
sorption sites (steric argument). The properties (stability,
affinity, expression yield) of scFv fragments can be engi-
neered through in vitro evolution in a yeast display format
[17–19]. The fact that scFv fragments can be produced
through microbial expression vectors provides greater
flexibility for the optimization of the production pro-
cess economics [20]. Furthermore, very high yields (3.1 g
scFv/L culture) of properly folded scFv fragments have
been expressed in and purified from the cytoplasm of Es-
cherichia coli [21]. These potential advantages of scFv
fragments, combined with the demonstrated affinity and
regeneration capacity of the immobilized BBM.1 anti-
body, motivated the development of an immunoadsor-
bent that is based upon a BBM.1 scFv fragment.
METHODS
Labeling of b2-m
Recombinant human b2-m was prepared as previously
described [16] and biotinylated using the FluoReporter
Biotin-XX Protein Labeling Kit (Molecular Probes,
Eugene, OR, USA). A 20 mg/mL working stock of
biotin-XX (sulfosuccinimidyl ester, sodium salt) in
dimethylsulfoxide (DMSO) was prepared and a tenfold
molar excess was added to 1.6 mg/mL b2-m in phosphate-
buffered saline (PBS), pH 7.4 (10 mmol/L PO4, 138
mmol/L NaCl, and 2.7 mmol/L KCl). The labeling re-
action was performed at this pH to inhibit the reaction
of the sulfosuccinimidyl ester with the primary amines
of lysine residues, thereby favoring the labeling of the
b2-m at the N-terminus. The reaction mixture was incu-
bated on a rocker for 90 minutes at room temperature
and subsequently dialyzed overnight into PBS 7.4 at 4◦C
to remove any unreacted biotin-XX using a 6 to 8 kD
membrane (Spectrum Laboratories, Rancho Dominguez,
CA, USA). The final concentration of b2-m was deter-
mined using an extinction coefficient of 20,065 M−1 cm−1
at 280 nm as previously described [16], while the degree of
biotinylation (0.93 mol biotin/mol b2-m) was determined
following the kit instructions.
Recombinant human b2-m was labeled with Alexa
Fluor 488 (carboxylic acid, succinimidyl ester), a flu-
orophore that is spectrally similar to fluorescein, but pos-
sesses greater brightness and photostability (Molecular
Probes). The protocol used was essentially that described
above for the biotinylation of b2-m. However, threefold
molar excess of a 5 mg/mL working stock of labeling agent
was added to 1.1 mg/mL of b2-m in PBS 7.4 for the la-
beling reaction. The final concentration and degree of
labeling (0.056 mol fluorophore/mol b2-m) was deter-
mined using the extinction coefficient previously de-
scribed [16], and the protocol provided by Molecular
Probes.
Cloning of VH and VL genes
The BBM.1 antibody-producing hybridoma cell line
(HB-28) was purchased from ATCC (Manassas, VA,
USA) and grown in T-flask static culture at 37◦C in a 5%
CO2 atmosphere. The growth media consisted of 90%
312 Grovender et al: Single-chain antibody adsorbent for b2-m
Aga2p
Aga1p
HA
V
LV
H
C-myc
scFv
s s
ss
Yeast cell wall
Yeast cell membrane
A
Aga2p
Aga1p
β2m
HA
V
LV
H
C-myc
s
s
s
s
Biotin Avidin-PE
Anti-mouse IgG
Anti-HA MAb
FITC
B
Fig. 2. Schematic diagram of yeast display. (A) The gene encoding the single-chain variable region antibody fragments (scFv) fragment of interest
is cloned into the pCT302 plasmid (or derivative) in frame with the Aga2p mating protein, which is under control of the GAL1,10 promoter. The
EBY100 strain of Saccharomyces cerevisiae possesses a single, integrated copy of the Aga1p gene, which is also under control of the GAL1,10
promoter. Upon induction by galactose, EBY100 cells transformed with pCT302 coexpress Aga1p and the Aga2p-scFv fusion. Aga1p is covalently
bound to the cell wall and the Aga2p-scFv fusion. (B) Anti-HA tag antibody, anti-c-myc tag antibody and labeled antigen can be used to characterize
the expression and activity of the scFv using a fluorescence-activated cell sorter (FACS). Objects are not drawn to scale.
RPMI 1640 medium (ATCC), 10% fetal bovine serum
(FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
The total RNA from 3 × 107 cells was isolated and reverse
transcription-polymerase chain reaction (RT-PCR) was
performed using the RNeasy Midi and the OneStep
RT-PCR Kits from Qiagen (Valencia, CA, USA). Vari-
ous combinations of the primers (0.5 lmol/L each) pro-
vided in the Mouse Ig-Primer Set (Novagen, Madison,
WI, USA) were used along with 1 lg of RNA and 40 units
of RNase inhibitor (Promega, Madison, WI, USA) in
50 lL RT-PCR reaction volumes. The thermocycler was
run for one RT cycle of 30 minutes at 50◦C, one DNA
polymerase-activation cycle of 15 minutes at 95◦C, 35 am-
plification cycles of 45 seconds at 94◦C, 1 minute at 60◦C,
1 minute at 72◦C, and 1 final extension cycle of 10 minutes
at 72◦C.
The PCR products were run on 1.2 or 2.0% agarose gels
stained with ethidium bromide. Those displaying bands
characteristic of VH and VL genes (about 500 base pairs in
length) were purified using the QIAquick Kit (Qiagen)
and ligated into the pSTBlue-1 plasmid (Novagen). The
ligation products were used to transform NovaBlue Sin-
glesTM competent cells (included in the pSTBlue-1 Per-
fectly Blunt Cloning Kit from Novagen), which were
plated onto Luria-Bertani (LB) medium agar plates con-
taining 50 mg/mL ampicillin. After incubating the plates
overnight at 37◦C, single colonies were each grown in
5 mL of LB containing 100–150 mg/L ampicillin at
37◦C overnight, and their plasmids were purified using
the QIAprep Spin Miniprep Kit (Qiagen). The DNA
inserts of the plasmid clones were sequenced and trans-
lated into peptide sequences so that they could be com-
pared to the partial peptide sequences obtained through
the N-terminal degradation of protein A–purified BBM.1
antibody.
Twenty-two cycles of N-terminal degradation were per-
formed on a sample of whole BBM.1 antibody. For each
degradation cycle, the two predominant residues were as-
signed to one of two peptide chains based on a match with
the published sequence of the MOPC-21 myeloma j light
chain [22]. This was done because the BBM.1 hybridoma
cell line (HB-28) was created by fusing an anti-b2-m B
cell with the X63-Ag8 myeloma [15], a descendent of the
MOPC-21 myeloma [23]. Both the X63-Ag8 and MOPC-
21 myeloma cell lines have been shown to secrete the
MOPC-21 j light chain as well as an IgG1 heavy chain
[23].
Display of scFv fragment by yeast
The VH and VL genes cloned from the BBM.1 hy-
bridoma were initially expressed as a scFv fragment in
a yeast display system [18] (Fig. 2). This approach was se-
lected because the b2-m binding affinity of the scFv could
readily be characterized in a quantitative fashion and, if
deemed necessary, would be in a vector that is amenable
to in vitro evolution [24].
Insert assembly. The scFv DNA insert was assembled
in a VH-(Gly4Ser)4-VL configuration via the splicing by
overlap extension (SOE) method [25]. All of the PCR
reactions were performed using Cloned Pfu DNA poly-
merase and Cloned Pfu Reaction Buffer (Stratagene,
La Jolla, CA, USA), following the manufacturer’s in-
structions except where otherwise noted. During the first
round of PCR, the VH and VL DNA inserts were ampli-
fied from the pSTBlue-1 plasmids (30 ng plasmid DNA
in each 50 lL reaction volume) using the custom primers
shown in Figure 3 (0.2 lmol/L each). The thermocycler
was run for one cycle of 45 seconds at 98◦C, 28 cycles of
45 seconds at 98◦C, 90 seconds at 72◦C, and one cycle of
10 minutes at 72◦C. The resulting VH and VL PCR prod-
ucts were purified using the QIAquick Kit and quanti-
tated by measuring their absorbance at 260 nm.
The second round of PCR was initiated without primers
and was performed in a single 50 lL reaction volume with
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Fig. 3. Custom primers used for polymerase chain reaction (PCR). The
assembly of the single-chain variable region antibody fragments (scFv)
insert by splicing by overlap extension (SOE) was performed using 5′-
VH, 3′-VH, 5′VL, and 3′-VL. The inserts for pEAG2 and pEAG3 we
made using 5′-VH, 3′-Arg-Asn, and 3′-His6-Cys. The 3′-VL-Arg-Asn
also reintroduces the 110 amino acid in the BBM.1 VL gene, which was
omitted from the 3′-VL primer. The sequences of the 3′ primers listed
are the reverse complement of those actually used.
77 ng of each VH and VL PCR product and 400 lmol/
L of each deoxynucleotide triphosphate (dNTP). The
thermocycler was run for five cycles of 1 minute at 96◦C,
1 minute at 53◦C, 2 minutes at 72◦C, and one cycle of
10 minutes at 72◦C. The 5′-VH and 3′-VL primers were
then added (0.5 lmol/L each) and the thermocycler was
run for 15 cycles of 1 minute at 96◦C, 1 minute at 53◦C,
1 minute at 72◦C, and one cycle of 10 minutes at 72◦C. The
resulting scFv DNA insert was purified and quantitated
as above.
Plasmid construction. The purified scFv SOE PCR
product and the pCTCON yeast display plasmid [26] (a
derivative of the pCT302 plasmid [18] with a BamHI
site added 5′ to the c-myc sequence) were digested with
BamHI and NheI restriction enzymes for more than 2
hours at 37◦C, according to the manufacturer’s instruc-
tions (New England Biolabs, Beverly, MA, USA). The
restriction digest products were purified using the QI-
Aquick Kit, combined in an equimolar ratio (500 ng
plasmid, 4 lg insert), and ligated using T4 DNA ligase
(Stratagene) following the manufacturer’s instructions.
After incubating the ligation reaction mixture at room
temperature for more than 2 hours, the reaction was heat
deactivated at 65◦C for 10 minutes. The ligation products
were used to transform XL1-Blue Supercompetent E. coli
(Stratagene), following the manufacturer’s protocol, and
plated on LB agar plates containing 50 mg/mL ampicillin.
Single colonies were each grown in 5 mL of LB containing
100 mg/L ampicillin at 37◦C overnight and their plasmid
clones were purified using the QIAprep Spin Miniprep
Kit. A plasmid clone with the desired in-frame scFv in-
sert was identified through DNA sequencing and labeled
pEAG1.
Yeast transformation, growth, and induction. EBY100
strain yeast cells [18] were transformed with pEAG1
through electroporation, plated onto SD-CAA agar
plates (7 g/L yeast nitrogen base, 5.4 g/L NaH2PO4,
8.6 g/L Na2HPO4, 5.0 g/L casamino acids, and 20 g/L dex-
trose, Trp and Ura deficient) and incubated for 2 1/2 days at
30◦C. Cells originating from a single colony were grown
in 5 mL of SD-CAA media (7 g/L yeast nitrogen base,
2.7 g/L NaH2PO4, 5.0 g/L Na2HPO4, 5.0 g/L casamino
acids, and 20 g/L dextrose) at 30◦C on an orbital shaker
for about 16 hours (OD600 = 4.0). A volume of the yeast
suspension containing 5 × 107 cells (OD600 = 1 represents
1 × 107 cells/mL [17]) was centrifuged, resuspended in
5 mL of SG-CAA induction media (same as SD-CAA,
but substituting galactose for dextrose), and incubated at
22◦C on an orbital shaker for approximately 20 hours.
Yeast labeling. The labeling of the yeast cells for flu-
orescence activated cell sorter (FACS) analysis was per-
formed in a fashion similar to that previously described
[27]. Each of a series of 1.5 mL centrifuge tubes were
loaded with 1 × 106 EBY100 cells (transformed with
pEAG1 and induced with galactose). The tubes were cen-
trifuged and the yeast pellets were washed with 500 lL
of PBS/bovine serum albumin (BSA) (PBS 7.4 with 0.1%
BSA added as a carrier). Murine anti-HA tag antibody
(12Ca5 Mab) (Roche, Basel, Switzerland) and biotiny-
lated recombinant human b2-m were used as primary
labeling agents at concentrations of 2 lg/mL and 1 ×
10−11 to 1 × 10−6 mol/L, respectively. The primary label-
ing of each tube was carried out in 1.0 mL of PBS/BSA at
room temperature on a rocker for 30 minutes. The cells
were spun down and washed as above with ice-chilled
PBS/BSA. Secondary labeling was conducted in 100 lL
of PBS/BSA on ice for 15 minutes, using 40 lL/mL each
of streptavidin-phycoerythrin (PE) (PharMingen, San
Diego, CA, USA) and flourescein isothiocyanate (FITC)-
conjugated ant-mouse IgG (Sigma Chemical Company,
St. Louis, MO, USA). The cells were centrifuged at 4◦C
and washed quickly with 500 lL of ice-chilled PBS/BSA.
The labeled cell pellets were stored on ice and protected
from light until FACS analysis.
Four additional yeast pellets were labeled for FACS
analysis, which served as controls. The labeling was per-
formed as described above, except that (1) the primary
labels were omitted; (2) biotinylated recombinant human
b2-m and streptavidin-PE were omitted; (3) the murine
anti-HA tag antibody and FITC-conjugated antimouse
IgG were omitted; and (4) unbiotinylated recombinant
human b2-m was added in 100-fold molar excess to com-
petitively inhibit the biotinylated b2-m.
FACS analysis. The labeled yeast cell pellets were each
resuspended in approximately 1.0 mL of PBS/BSA and
analyzed with an Epics XL FACS (Beckman Coulter,
Fullerton, CA, USA) in a fashion similar to those pre-
viously described [17, 27]. Samples were gated by light
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scattering and then by FITC signal in order to avoid
consideration of particles other than un-clustered scFv-
displaying yeast cells. The mean PE signal for more than
2 × 104 scFv-displaying cells labeled with each b2-m con-
centration was recorded. SPHEROTM Rainbow Calibra-
tion Particles (3.0 to 3.4 lm) (Spherotech, Libertyville,
IL, USA) with six different known densities of surface-
immobilized FITC were also analyzed (>1 × 103 counted
at each density) to allow for the correlation of the mean
FITC signal per cell to the mean number of scFv frag-
ments displayed by each cell.
Mathematical modeling. Assuming a monovalent
antibody-antigen binding interaction, the antibody-
antigen equilibrium dissociation constant, KD, is defined
in equation 1:
KD ≡ [scFv]eq[b2m]eq[scFv × b2m]eq (1)
where [scFv]eq, [b2-m]eq, and [scFv × b2-m]eq are the
equilibrium concentrations (mole per liter of cell sus-
pension during primary labeling) of dissociated antibody
fragment, dissociated antigen (b2-m), and scFv fragment
antigen complex, respectively.
Assuming that the binding of b2-m by the scFv frag-
ment is the only reaction consuming the dissociated
species, [scFv]eq and [b2-m]eq can be expressed in terms
of other variables as described in equations 2 and 3:
[scFv]eq = [scFv]0 − [scFv × b2m]eq
= P0[Y]0 − [scFv × b2m]eq (2)
[b2m]eq = [b2m]0 − [scFv × b2m]eq (3)
where [scFv]0, [b2-m]0, and [Y]0 are the initial molar con-
centrations of dissociated antibody fragment, b2-m, and
yeast cells during the primary labeling step and P0 is
the mean number of scFv fragments displayed per cell
(mol scFv/mol yeast). The value of P0 was independently
determined from the mean FITC signal and the cali-
bration curve obtained from the FACS analysis of the
SPHEROTM standards.
The mean PE signal of the scFv displaying population,
F, is assumed to be a linear function of [scFv × b2-m]eq
as described by equation 4:
F = c1[scFv × b2m]eq + c2 (4)
where c1 and c2 are empirical constants.
Equations 1 to 4 can be combined and rearranged to
yield equation 5:
F = c1
2
[
(KD + [b2m]0 + P0[Y]0)
−
√
(KD + [b2m]0 + P0[Y]0)2 − 4P0[Y]0[b2m]0
]
+ c2
(5)
which was used to regress the values of KD, c1, and c2
from each set of F vs. [b2-m]0 data.
Secretion of scFv fragment by yeast
A His6-tag and a cysteine residue were added to the
C-terminus of the secreted version of the BBM.1 scFv
fragment to facilitate its purification and subsequent im-
mobilization. This location was chosen to minimize the in-
terference of the purification tag and the immobilization
bond with the b2-m binding site. It was deemed necessary
to remove the Lys-Arg sequence near the C-terminus of
the VL gene because it is known to be cleaved by the
Kex2 protease within the trans-Golgi network of Saccha-
romyces cerevisiae [28, 29].
Plasmid construction. The Lys-Arg sequence in the
VL was removed by changing the Arg residue to Asn. This
was achieved through PCR (50 lL reaction volume) with
the 5′-VH and 3′-Lys-Asn primers (Fig. 2) (0.25 lmol/L
each) and the pEAG1 plasmid (1 lL). Cloned Pfu DNA
polymerase and Cloned Pfu Reaction Buffer were used
to carry out the reaction, following the manufacturer’s
instructions. The thermocycler was run for one cycle of
1 minute at 98◦C, 28 cycles of 1 minute at 98◦C, 2 min-
utes at 72◦C, and one cycle of 10 minutes at 72◦C. The
resulting scFv PCR product was ligated into the pCT302
plasmid essentially as described for the construction of
the pEAG1 plasmid, except that a 2:1 molar ratio of
scFv insert to plasmid DNA was used during the ligation
reaction. A plasmid clone with the desired scFv insert,
pEAG2, was obtained from the ligation reaction prod-
ucts in the same manner as pEAG1.
The Kex2 protease resistant form of the BBM.1 scFv
insert was amplified from the pEAG2 plasmid through
PCR with the 5′-VH and 3′-His6-Cys primers (Fig. 3).
The PCR was performed as described for the creation
of pEAG2, except that the thermocycler was run for one
cycle of 1 minute at 98◦C, 28 cycles of 1 minute at 98◦C,
1 minute at 55◦C, 1 minute at 72◦C, and one cycle of
10 minutes at 72◦C. The resulting scFv insert was ligated
into the secretion plasmid pRS-GALTwt [30] in frame
with the synthetic pre pro signaling sequence [31], under
control of the GAL1,10 promoter. The ligation protocol
was essentially that described for the construction of the
pEAG1 from pCTCON, except that the BamHI restric-
tion enzyme was replaced with XhoI (New England Bio-
labs) and a 4:1 molar ratio of scFv insert to plasmid DNA
was used. A secretion plasmid clone with the desired scFv
insert, pEAG3, was obtained from the ligation reaction
products in the same manner as pEAG1 and pEAG2.
Yeast transformation, growth, and induction. YVH10
yeast, a protein disulfide isomerase overexpressing strain
of Saccharomyces cerevisiae [32], was transformed with
pEAG3 and pRS314 (to add Trp resistance to allow se-
lection on Trp-deficient media) [33] using the lithium
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acetate/single-stranded carrier DNA/polyethylene glycol
method [34]. Cells were plated onto selective SD-SCAA
plates [6.7 g/L yeast nitrogen base, 7.5 g/L NaH2PO4,
5.4 g/L Na2HPO4, 20 g/L dextrose, 15 g/L agar, 182 g/L
sorbitol, and synthetic casamino acids (40 mg/L adenine
sulfate, 140 mg/L His, 190 mg/L Arg, 108 mg/L Met,
52 mg/L Tyr, 290 mg/L Ile, 440 mg/L Lys, 200 mg/L Phe,
1260 mg/L Glu, 400 mg/L Asp, 380 mg/L Val, 220 mg/L
Thr, and 130 mg/L Gly, deficient in Leu, Trp, and Ura)]
and incubated at 30◦C for 3 days.
Expansion of the transformed YVH10 cells was ini-
tiated by inoculating 50 mL of SD-SCAA liquid media
(same as SC-SCAA plates, but with agar and sorbitol
omitted) with cells originating from a single colony. Af-
ter incubating the starter culture on an orbital shaker at
30◦C overnight (OD600 = 3.6), 30 mL of the starter culture
was used to inoculate 6 L of SD-SCAA. Each liter of SD-
SCAA was placed into a 2.5 L fully baffled Tunair flask
(Shelton Scientific, Shelton, CT, USA) and incubated at
30◦C for 1 day (OD600 = 6.8). The yeast cells were then
centrifuged and resuspended in 6 L of 10 g/L yeast extract,
20 g/L peptone, 20 g/L galactose (YPG) induction media
with 100 U/mL penicillin and 0.1 g/L streptomycin added
to inhibit bacterial contamination. Each liter of YPG was
placed in a 2 L, smooth-bottomed Erlenmeyer flask and
incubated at room temperature (approximately 22◦C) for
about 3 days (OD600 = 17.4). The cell suspension was then
centrifuged and the supernatant was 0.2 lm filtered and
concentrated to an approximate volume of 400 mL using
a 10 kD Prep/Scale-TFFTM-regenerated cellulose mem-
brane (Millipore, Bedford, MA, USA).
Protein purification. The His6-tagged scFv fragment
was purified from the concentrated cell culture super-
natant via nickel affinity chromatography, for which PBS
8.0 (50 mol/L phosphate, 300 mmol/L sodium chloride)
was used with varying imidazole concentrations. To re-
move metal contaminants, 5 mmol/L sodium ethylene-
diaminetetraacetic acid (EDTA) was added to the con-
centrated culture supernatant, which was placed in a
400 mL stirred ultrafiltration cell with a 10 kD YM10
regenerated cellulose disk membrane (Millipore). The
cell was subsequently flushed with 2.8 L of PBS 8.0 to
facilitate buffer exchange. To minimize the binding of
untagged protein, 10 mmol/L imidazole was added and
the protein was bound to a 5 mL column of Ni-NTA
agarose gel beads (Qiagen). The resin was washed with
60 mL of 20 mmol/L imidazole and eluted with 30 mL
of 250 mmol/L imidazole. The eluted protein was further
purified by size-exclusion chromatography using Super-
ose 12 prep grade resin (Amersham Biosciences, Upp-
sala, Sweden) eluted with PBS 7.4. The desired fractions
were pooled and the concentration of scFv was measured
by reading the absorbance at 280 nm, using a molar ex-
tinction coefficient of 51,130 L/mol cm−1 and a molecu-
lar weight of 29,032 g/mol. These values were calculated
from the amino acid sequence and the formula reported
by Pace et al [35].
Immunoadsorbent based on scFv fragment
Protein immobilization. Immediately prior to im-
mobilization, the purified scFv fragment was reduced
with Immobilized TCEP (Tris[2-carboxyethyl] phos-
phine hydrochloride]) Disulfide Reducing Gel (Pierce,
Rockford, IL, USA). The reaction was performed for
1 hour at room temperature on a rocker in 3.5 mL of
PBS 7.2 (100 mmol/L PO4 and 150 mmol/L NaCl) con-
taining 15 mmol/L EDTA, 33% TCEP gel by volume, and
2.0 mg/mL scFv fragment. During the same hour, lysine
Sepharose 4B (Amersham Biotech) was activated with
sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (Sulfo-SMCC) (Pierce). Sulfo-SMCC is a
heterobifunctional cross-linking agent that reacts with
sulfhydryl and primary amine groups. This reaction was
also performed for 1 hour at room temperature on a
rocker, but in 4.5 mL of 150 mmol/L sodium bicarbon-
ate buffer (pH 8.8) containing 1.8 mg/mL Sulfo-SMCC
and 22% swollen lysine Sepharose 4B gel by volume.
Following the 1-hour incubation, the activated lysine
gel was rinsed (several times, totaling 30 volumes) and
resuspend with ice-cold PBS 7.2. Immediately there-
after, the reduced scFv fragment was removed from
the TCEP gel by centrifuging it in a Micro BioSpin
(BioRad, Hercules, CA, USA) column. The TCEP gel
was rinsed with 1.0 mL of PBS 7.2 to improve the re-
covery of the scFv fragment. The scFv fragment im-
mobilization reaction was performed for 24 hours on
a rocker at 4◦C in 4.0 mL PBS 7.2 containing 4.4 mg
scFv fragment and 0.45 mL Sulfo-SMCC activated gel
(settled bed volume). The number free thiol groups per
scFv fragment molecule, before and after contact with
the TCEP gel, was measured using the Thiol and Sul-
fide Quantitation Kit obtained from Molecular Probes.
The kit instructions were followed except that the de-
gassing performed by argon bubbling instead of using
vacuum desiccator.
The following day, the soluble scFv fragment was re-
moved from the gel by centrifuging it in a Micro Bio-
Spin column and the gel was rinsed four times with
2.0 mL of PBS 7.2. The gel was re-suspended in 2.0 mL
PBS 7.2, containing 1 mmol/L L-cysteine as a quenching
agent, and incubated overnight at 4◦C on a rocker. Af-
ter quenching, the gel was centrifuged, rinsed four times
as before, and resuspended in PBS 7.4. Equal volumes
of the reduced scFv fragment, the quenching buffer, and
the eight rinses were assayed for protein by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). A control matrix was prepared by immobilizing
L-cysteine onto lysine Sepharose 4B gel following the
above protocol, omitting the scFv-protein.
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Characterization. Alexa Fluor 488-labeled recom-
binant human b2-m (b2m-AF488, see “Labeling of b2-
m” section) was used to determine the b2-m adsorption
capacity of the agarose-immobilized scFv antibody frag-
ment and control matrix. A series of 0.5 mL centrifuge
tubes were each loaded with 100 lL of 10% gel suspen-
sion in fetal calf serum (FCS)/PBS (75% FCS, 25% PBS
7.4, by volume), a saturating quantity of b2-m-AF488 (16,
12, or 10 lg; 0.96 mg/mL stock), and sufficient FCS/PBS
to bring the total volume to 0.400 mL. The tubes were
equilibrated at 37◦C for 1 hour on a rocker and then cen-
trifuged. From each tube, three 100 lL volumes of su-
pernatant were loaded into individual wells of a 96-well
plate, which was also loaded with calibration standards (0,
10, 20, 30, 40, and 50 mg/L of b2-m-AF488 in FCS/PBS).
The plate was read by a Mithras LB 940 plate reader
(Berthold Technologies, Bad Wildbad, Germany), using
excitation and emission wavelengths of 485 and 535 nm,
respectively. A linear calibration curve was generated and
was used to determine the b2-m-AF488 concentrations of
the experimental samples. The b2m-adsorption capacity
of the agarose-immobilized scFv antibody fragment was
calculated from this data, using equation 6:
qs = VtotalVgel (C0 − Ceq) (6)
where qs is the adsorption site density (mg b2-m per mL
of settled gel), Vtotal is the total volume of each tube (mL),
Vgel is the settled-volume of the gel (lL), C0 is the initial
b2-m concentration (mg/L), and Ceq is the concentration
of desorbed b2-m at equilibrium (mg/L).
For regeneration, the labeled gel was recovered from
the centrifuge tubes, placed in a Micro Bio-Spin col-
umn, and centrifuged. The immunoadsorptive media was
regenerated by rinsing it four times with 2.0 mL of strip-
ping buffer (300 mmol/L glycine, pH 2.8). The regener-
ated media was rinsed four times with 2.0 mL of PBS 7.4,
and then rinsed once and resuspended with FCS/PBS to
make a 10% suspension. The adsorption capacity of the
regenerated immunoadsorptive media was measured as
above.
The affinity of the regenerated immunoadsorptive me-
dia for b2-m was assessed by following the protocol used
to determine the adsorption capacity, except that each
tube was loaded with twice the amount of gel along with
a sub-saturating quantity of b2-m-AF488 (6 lg). The cal-
ibration standards also spanned a lower concentration
range (0, 0.5, 1.0, 2.5, 5.0, 10, or 15 mg/mL).
Leaching of the scFv fragment by the stripping buffer
was assayed through Western blotting. Diluting it with 13
mL of 100 mmol/L sodium phosphate, 1 mmol/L EDTA,
pH 8.0, neutralized each 2.0 mL volume of stripping
buffer. Equal volume samples of the neutralized strip-
ping buffer and similarly diluted scFv from the immo-
bilization reaction were run on SDS-PAGE with 5%
2-mercaptoethanol added to the sample buffer as a re-
ducing agent. A polyvinylidene difluoride (PVDF) mem-
brane was used for blotting, which was labeled with
anti-His horseradish peroxidase (HRP) conjugate (us-
ing the included anti-His HRP conjugate blocking
buffer) following the manufacturer’s instructions (Qia-
gen). However, PBS 7.4 was used instead of Tris-buffered
saline. Colorimetric detection was performed using the
Opti-4CNTM Substrate Kit (BioRad), again following
manufacturer’s instructions.
The specificity of the scFv-based immunoadsorbent
was evaluated via the immunoprecipitation of radiola-
beled cell lysate obtained from a human white cell line.
U373-MG astrocytoma cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
5% FCS and 5% calf serum. Radiolabeling of cells
was essentially performed as described in [36]. Briefly,
cells were incubated in starvation medium (cysteine- and
methionine-free DMEM supplemented with 5% FCS,
5% calf serum) for 1 hour at 37◦C at a density of 106 cells/
mL. Cells were then labeled for 3 hours at 106 cells
per 100 lL of starvation medium containing 500 lCi
of [35S]methionine-cysteine (1200 Ci/mmol) (NEN-
Dupont, Boston, MA, USA)/mL. Cells were then lysed
in lysis buffer (10 mmol/L Tris, pH 7.8, 150 mmol/L
NaCl, 5 mmol/L MgCl2, and 0.5% NP-40) supplemented
with 1.5 lg of aprotinin per mL, 1 lmol/L leupeptin,
and 2 mmol/L phenylmethylsulfonyl fluoride (PMSF).
Unlysed cells and cellular debris were subsequently
removed by centrifugation at 13,000g for 10 minutes.
For immunoprecipitation of b2-m, scFv-coupled agarose
beads were mixed with “empty” control agarose beads
at various ratios while maintaining a constant quantity
of agarose beads in each reaction. Beads were incu-
bated with the 35S-labeled cellular extracts for 45 minutes
under constant agitation and the pelleted immunopre-
cipitates were subsequently washed three times with
washing buffer (0.5% NP-40, 50 mmol/L Tris, pH 7.4,
150 mmol/L NaCl, and 5 mmol/L EDTA). As a posi-
tive control, b2-m was immunoprecipitated by the use
of anti-b2-m antibodies (BBM.1) [15] and formalin-fixed
heat-killed Staphylococcus aureus cells, essentially as de-
scribed [36].
Statistical analysis
Measured quantities are reported as the mean ± the
standard error of the mean (SEM), except for the scFv
immobilization density and the mass ratio of adsorbed
b2-m to immobilized antibody, for which the error esti-
mates correspond to the accuracy of the gel volume mea-
surement. The significance of the difference between two
means was tested by analysis of variance (ANOVA) using
a two-tailed P value of 0.05. Regressions were performed
by minimizing the summed square error (SSE).
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Fig. 4. VH and VL genes cloned from the BBM.1 hybridoma.
RESULTS
Cloning of VH and VL genes
As resolved by agarose gel electrophoresis, one com-
bination of the Ig-Prime Kit heavy chain primers
(MuIgVH5′-D and MuIgVH3′-2) and three combinations
of the light chain primers (MuIgjVL5′-B, MuIgjVL5′-
C, and MuIgjVL5′-E, each with MuIgjVL3′-1) yielded
RT-PCR products that were characteristic of VH and
VL genes (approximately 400 base pairs in length). The
DNA sequences of two of the VL RT-PCR products
(MuIgjVL5′-B and MuIgjVL5′-C) were found to match
the aberrant light chain sequence listed in the Ig-Prime
Kit instructions [37] and were discarded. The sequences
of the remaining VH and VL genes (Fig. 4) were trans-
lated and compared to the peptide sequencing results of
the protein A-purified BBM.1 antibody.
Three different peptide chains were detected by N-
terminal degradation, where only two were expected for a
pure monoclonal. The signal for one of the peptide chains
was too weak to determine its sequence with a high level
of confidence, while the two predominant peptide chains
were found in approximately equal proportions. The se-
quence of the MOPC-21 j light chain was used to infer the
sequence of the second peptide chain in the BBM.1 anti-
body sample. This peptide sequence matched the cloned
VH sequence, but did not match that of the MOPC-21
heavy chain [38]. Meanwhile, the sequence of the cloned
VL gene did not match the sequence of the MOPC-21
j light chain. These findings suggested that the cloned
VH and VL genes belonged to the anti-b2-m antibody
secreted by the BBM.1 hybridoma.
Display of scFv fragment by yeast
The ability of the cloned VH and VL genes to bind b2-
m was confirmed by expressing them as a scFv fragment
in a yeast display format. The addition of 100-fold molar
excess unbiotinylated b2-m effectively inhibited the bind-
ing of the biotinylated b2-m, while the average number
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Fig. 5. Titration of BBM.1-single-chain variable region antibody frag-
ments (scFv) displaying yeast with fluorescent b2-microglobulin (b2-m).
Aliquots of EBY100 cells transformed with pEAG1 and displaying wild-
type BBM.1-scFv fragment were labeled with various concentrations of
biotinylated b2-m. Streptavidin-phycoerythrin (PE) was used to label
the adsorbed b2-m. The mean PE signal of the scFv displaying popula-
tion of each east aliquot was measured by a fluorescence-activated cell
sorter (FACS). Error bars represent standard error of the mean (SEM).
Fig. 6. The single-chain variable region antibody fragments (scFv)
fragment secreted by YVH10 yeast transformed with pEAG3. The full
sequences of the VH and VL genes are given in Fig. 4.
of scFv fragments displayed by the pEAG1-transformed
yeast was 2. × 104 ± 0.3 × 104 mol scFv/mol yeast (P0).
The three FACS titration curves that were used to de-
termine the value of the scFv-b2-m dissociation equilib-
rium constant are summarized in Figure 5 (KD = 0.7 ±
0.3 nmol/L = 0.008 ± 0.004 mg-b2-m/L). Based on these
results, it was concluded that the cloned VH and VL genes
belong to the anti-b2-m antibody produced by the BBM.1
cell line.
Secretion of scFv fragment by yeast
Figure 6 gives the sequence of the secreted scFv frag-
ment, while Figure 7 demonstrates the purity of the scFv
fragment after purification by nickel affinity chromatog-
raphy. One minor peak and two major peaks were eluted
from the size-exclusion column (as resolved by monitor-
ing the absorbance at 280 nm). The minor peak corre-
sponded to the exclusion limit of the resin, while the
two major peaks (approximately the same size) corre-
sponded to the molecular weights of the scFv fragment
and its dimer. The fractions from the two major peaks
were pooled to improve the yield of scFv fragment prepa-
ration and used to produce the immunoadsorptive media.
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ScFv dimer
ScFv monomer
Non-reduced Reduced
Fig. 7. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) of the secreted BBM.1-single-chain variable region an-
tibody fragments (scFv) fragment after nickel affinity purification. The
reduced sample was treated with 5% betamercaptoethanol and boiled
for 5 minutes to dissociate the scFv dimer.
The yield of purified scFv fragment per unit volume of
culture was 1.5 mg/L.
Immunoadsorbent based on scFv fragment
The TCEP reducing gel increased the molar ratio of
free thiol groups to scFv fragments from less than 0.1%
to 50%. At the end of the immobilization reaction, 25% of
the total, or 50% of the reduced scFv fragment, had bound
to the Sulfo-SMCC-activated gel. This corresponds to
an immobilization density of 2.4 ± 0.2 mg scFv/mL set-
tled gel. No leaching of the scFv fragment from the
immunoadsorbent was detected in the PBS rinses (SDS-
PAGE), cysteine quenching buffer (SDS-PAGE), or in
the neutralized stripping buffer (Western blot).
The observed b2-m adsorption site density (qs) did not
significantly depend on the b2-m concentration under sat-
urating conditions, nor did it significantly change after
one round of regeneration (Table 1). The average mea-
sured value of qs was 0.41 ± 0.01 mg b2-m/mL settled gel,
which corresponds to a binding activity of 42% (molar
ratio of adsorbed b2-m to immobilized scFv fragment)
for the immobilized scFv fragment. Under subsaturat-
ing conditions (C0 = 15 mg/mL), the regenerated im-
munoadsorbent possessed sufficient affinity to bring the
concentration down to Ceq = 1.0 ± 0.1 mg/L (N = 5).
The immunoprecipitation experiments with radiolabeled
cell lysate from the human cell line U373-MG (astrocy-
toma cells) suggest a high degree of specificity of the im-
munoadsorbent toward soluble and complexed (with the
heavy chain of MHC I) b2-m (Fig. 8).
DISCUSSION
The removal of b2-m from human blood plasma has
previously been investigated with immunoadsorbents
consisting of whole anti-b2-m antibodies immobilized
onto porous beads [39–42]. These small-scale affinity
chromatography experiments have demonstrated that an
immunoadsorbent can remove b2-m from human plasma
with an affinity that has not been achieved with hy-
drophobic interaction-based adsorbents [6, 7]. Further-
more, these antibody-based adsorbents were found to
be highly specific for b2-m, while the specificity of hy-
drophobic interaction-based adsorbents continues to be a
concern [8, 10]. To date, perhaps the most promising anti-
b2-m immunoadsorbent has been reported by Vallar et al
[41], which consisted of monoclonal antibodies immobi-
lized onto Sepharose CL-4B gel beads. This adsorbent
was highly regenerable and possessed a b2-m adsorption
site density (0.9 mg b2-m/mL settled gel) that is expected
to be sufficient, but not optimal for actual clinical appli-
cation (i.e., 350 mL settled volume of adsorbent required
to remove 315 mg of b2-m).
While the results of these preliminary investigations
are encouraging, the challenge of removing b2-m from
whole blood in a single extracorporeal device has not
been addressed until recently [16]. More specifically, we
have successfully removed low concentrations of b2-m
(3.2 mg/L) from whole human blood in vitro at a thera-
peutically relevant flow rate (200 mL blood/min) using a
novel, plasmapheretic extracorporeal device (the VFPR)
and an immunoadsorbent based on whole BBM.1 anti-
bodies. The concentration of b2-m that was cleared by
the VFPR device was limited by a low b2-m adsorp-
tion site density (qs = 0.030 ± 0.002 mg b2-m/mL set-
tled gel), which was caused by the low molar binding
activity of the immobilized BBM.1 antibody (only 6%
of the immobilized antibody-bound b2-m). Nevertheless,
the immobilized whole antibodies (BBM.1) that retained
binding activity demonstrated a high affinity for b2-m
(KD = 0.1 ± 0.1 mg/L) as well as the ability to be re-
generated repeatedly (>10×) without a detectable loss
of binding activity. At the time, we hypothesized that the
low b2-m adsorption site density was either caused by
the excessive deactivation of the monoclonal antibody by
the immobilization chemistry (cyanogen bromide activa-
tion of agarose) and/or the expression of an additional,
unwanted immunoglobulin chain (impurity) by the hy-
bridoma cell line.
Research into the origin of the BBM.1 antibody-
producing hybridoma cell line (HB-28) has revealed that
it was created using the X63-Ag8 myeloma [15], which
has been shown to secrete the MOPC-21 j light and
IgG1 heavy chains [23, 38]. In light of this fact, pro-
tein A–purified BBM.1 antibody was partially sequenced
through N-terminal degradation. The results suggest that
the protein sample primarily consisted of the MOPC-21
light chain and an IgG heavy chain other than the MOPC-
21 IgG1 chain (presumably the anti-b2-m heavy chain),
with a trace amount (<10%) of a third peptide chain
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Table 1. b2-microglobulin adsorption site density of the immunoadsorptive media (qs)
Initial b2-m concentration, C0 mg/L
40 30 25 Mean Significance
Before regeneration mg b2-m/mL settled gel N = 3 0.33 ± 0.04a 0.41 ± 0.01 0.48 ± 0.05 0.40 ± 0.04 P > 0.2
After regeneration mg b2-m/mL settled gel N = 5 0.41 ± 0.02 0.44 ± 0.02 0.43 ± 0.01 0.43 ± 0.01 P > 0.6
Mean mg b2-m/mL settled gel 0.41 ± 0.01
Significance (adsorption site density before and after regeneration) P > 0.2
Various initial concentrations (C0) of b2-m AF488 were equilibrated with 10 lL volumes of the immunoadsorptive media (Vgel) in 0.400 mL fetal calf serum (FCS)
phosphate-buffered saline (PBS) (Vtotal) at 37◦C for 1 hour. The equilibrium concentration of desorbed b2-m AF488 (Ceq) was measured and used to calculate the b2-m
adsorption site density (qs) using equation 6. These experiments were conducted on the immunoadsorptive media before and after regeneration with 0.3 mol/L glycine,
pH 2.8.
aN = 2
0
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Fig. 8. Human b2-microglobulin (b2-m) is specifically precipitated by
(BBM.1) agarose immobilized single-chain variable region antibody
fragments (scFv). ScFv antibodies coupled to agarose beads were mixed
with untreated agarose beads to maintain a constant volume of beads in
each reaction. The numbers above lanes 1 to 5 indicate the percentage
of beads with bound scFv used in each reaction. Lane 7 shows proteins
precipitated using the monoclonal antibody BBM.1 and fixed Staphy-
lococcus aureus as a positive control. Lane 6 is empty. Indicated on the
right are the migration positions of b2-m and coprecipitating class I
MHC heavy chain (HC). The heavy chain signal appears stronger than
that of the b2-m because it has a larger number of cysteine and methio-
nine (the radiolabeled amino acids) relative to b2-m. See the Methods
section for details.
(presumably the anti-b2-m light chain). The apparent ab-
sence of MOPC-21 IgG1 in the protein sample can be
explained by the fact that protein A is known to bind to
IgG2b with a higher affinity than IgG1 [43] and that the
BBM.1 antibody has been classified as IgG2b [15].
The optimization of an immunoadsorbent for the ex-
tracorporeal removal of b2-m will require the maximiza-
tion of the b2-m adsorption site density to minimize the
required volume of immunoadsorbent. The volume of
immunoadsorbent contained within the extracorporeal
device is an important parameter for the optimization
of biocompatibility, as it is proportional to the amount
of blood plasma retained during therapeutic operation.
One strategy for achieving higher b2-m adsorption site
densities is to use scFv antibody fragments as immunoad-
sorption ligands instead of significantly larger whole an-
tibodies (1 mg of scFv fragment can bind 0.4 mg of
b2-m, whereas 1 mg of whole antibody can only bind
0.16 mg of b2-m). Another advantage of scFv fragments
over whole antibodies is their ability to be expressed by
microbial vectors. This makes scFv fragments amenable
to in vitro evolution in a convenient yeast display format
and provides more options for process optimization, po-
tentially resulting in a significant reduction in production
cost. ScFv fragments are also genetically defined, which
offers the opportunity to eliminate the expression of un-
wanted peptide chains by the source hybridoma cell line.
Motivated by the potential advantages of scFv frag-
ments, the desirable affinity and regeneration capacity of
BBM.1, and the apparent MOPC-21 j light chain con-
tamination, we created an immunoadsorbent for the re-
moval of b2-m that is based on BBM.1 scFv fragments.
The BBM.1 scFv was first expressed in a yeast display for-
mat to facilitate the characterization of its phenotype and
to enable the engineering of its properties (i.e., stability
and/or regeneration capacity under various conditions)
through in vitro evolution, if it is desired in the future.
The binding affinity of the yeast-displayed scFv frag-
ment for b2-m was quantitated by FACS analysis. The
measured value of KD (0.7 ± 0.3 nmol/L = 0.008 ±
0.004 mg/L) is in agreement with that previously re-
ported for the agarose-immobilized whole BBM.1 an-
tibody (0.1 ± 0.1 mg/L) [44]. This result is noteworthy
from an antibody engineering perspective, because the
conversion of a whole antibody to a wild-type scFv frag-
ment can result in a significant decrease in affinity [45].
Furthermore, our reported value for KD is well below the
b2-m concentration range expected in the blood plasma
of healthy individuals (1.0 to 3.0 mg/L) [14]. Hence,
the yeast-displayed wild-type BBM.1 scFv fragment pos-
sesses an affinity for recombinant human b2-m that is
optimal for the clinical treatment of DRA through extra-
corporeal immunoadsorption.
Given the encouraging binding affinity of the yeast-
displayed antibody fragment, the scFv gene (a Kex2
protease-resistant version) was expressed by a yeast se-
cretion vector. The selected protein expression and pu-
rification methods produced enough of the scFv fragment
so that a small volume of a model scFv immunoadsor-
bent could be produced for investigational purposes. The
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molar binding activity (42%) and the b2-m adsorption
site density (qs = 0.41 ± 0.01 mg b2-m/mL settled gel) of
the scFv-based adsorbent are significantly greater than
those measured for the whole BBM.1 antibody-based
adsorbent (molar binding activity of 6%, qs = 0.030 ±
0.002 mg b2-m/mL settled gel). This improvement can
be attributed to the elimination of the production of the
MOPC-21 light chain by the cloning procedure. Hence,
this work demonstrates how the creation of a wild-type
scFv fragment from an existing hybridoma cell line can
be used to separate desired antibody genes from contam-
inating ones. Under saturating conditions (Ceq 
 KD),
the mass ratio of adsorbed b2-m to immobilized anti-
body (0.17 ± 0.02 mg b2-m/mg scFv) is roughly equiv-
alent to the theoretical limit for 100% active, bivalent
whole IgG antibody (0.16 mg b2-m/mg antibody) and
70% higher than that actually achieved by Vallar et al
[41] (0.1 mg b2-m/mg antibody). Shabunina, Afanas’eva,
and Pokrovskii [42] have immobilized whole, polyclonal
anti-b2-m antibodies onto Sepharose CL-4B at den-
sities that range from 2 to 16 mg/mL settled gel. Over
this range the mass ratio of adsorbed b2-m to immobi-
lized antibody remained constant (0.04 mg b2-m/mg an-
tibody). If this immobilization density can be achieved
for the BBM.1 scFv while maintaining a molar binding
activity of 42%, a new immunoadsorbent with a b2-m
adsorption site density of 2.7 mg b2-m/mL settled gel
could theoretically be produced. This would represent a
threefold increase over the b2-m adsorption site density
reported by Vallar and co-workers [41], which is the
highest reliable value reported in the literature. Mogi
et al [39] reported a b2-m adsorption site density of
4.3 mg/mL. However, this value is not reliable because
their reported antibody immobilization density (18.8 mg
antibody/mL gel) corresponds to a mass ratio of adsorbed
b2-m to immobilized antibody (0.23 mg b2-m/mg anti-
body) that is well above the theoretic limit (0.16 mg
b2-m/mg antibody). In the present work, we also inves-
tigated the specificity of the agarose-immobilized scFv
in vitro, as this property is important for clinical appli-
cation. The introduction of specific protein clearance to
dialysis therapies via scFvs would eliminate the loss of
middle molecular weight proteins that are important to
the patient. It would also allow specific removal of large
proteins (>40 kD) that are suspected to mediate or cause
disease but cannot be removed via conventional size
exclusion-based methods. Specificity of the immunoad-
sorbent should be ultimately evaluated during perfusion
of human blood; nevertheless, we can obtain some in-
sight into this property through immunoprecipitation of
b2-m from the lysate of astrocytoma cells. This human cell
line is commonly used in studies investigating the MHC
I complex. These cells secrete b2-m (along with hun-
dreds of other human proteins) and also express MHC
I on the cell surface. As expected, our results showed
that non-specific binding to the immunoadsorbent was
insignificant.
The presence of the heavy chain band in Figure 8
suggests that the fragment was able to recognize free
monomeric, soluble b2-m as well as b2-m bound to the
heavy chain of the MHC I complex. This coprecipitation
of the heavy chain was also observed with the positive
control; the hybridoma-produced monoclonal antibody
BBM.1 (which has been shown to bind free and MHC
I-bound b2-m with similar affinity [15]). This finding is
not unexpected as BBM.1 monoclonal antibody was orig-
inally a product from the immunization of mice with
cells expressing human MHC I. Furthermore, the anti-
genic epitopes on b2-m are not involved in MHC I heavy
chain interactions [15, 46]. The ability of our scFv to
bind soluble as well as MHC I-bound b2-m suggests that
it recognizes the same epitopes as its parent antibody,
BBM.1 (epitopes that are normally exposed). This par-
ticular recognition ability has interesting implications for
the removal of nonglycosylated “amyloidogenic” forms
of b2-m from blood (such as partly denatured or desta-
bilized monomeric b2-m species in solution, which have
been shown to have a higher propensity to fibril forma-
tion relative to the properly folded protein [47–52]). Re-
cent publications regarding the amyloidogenic potential
of monomeric b2-m suggest that the epitope recognized
by BBM.1 remains in its native-like configuration despite
a global partially folded state in solution [50, 53, 54].
(BBM.1 as well as the scFv can bind b2-m that is prop-
erly folded as well as denatured via SDS, data not shown).
Partly denatured forms of b2-m, although a small percent-
age of total b2-m in solution (∼14%), may one day prove
to be important targets to delay amyloid formation [50,
51, 54, 55].
To the best of our knowledge, this is the first time that
a scFv-based adsorbent for the extracorporeal removal
of b2-m has been reported. Under saturating conditions,
this new type of immunoadsorbent binds a mass ratio
of adsorbed b2-m to immobilized antibody that is above
the theoretic limit obtainable with whole antibodies. Fu-
ture work will involve the optimization of the scFv frag-
ment expression, purification, and immobilization meth-
ods. Larger volumes (100 to 200 mL) of this scFv-based
immunoadsorbent will be produced and used within a
VFPR device to remove pathologic levels (20 to 60 mg/L)
of b2-m from human blood. We expect that the immobi-
lization density of the scFv fragment can be increased
sufficiently such that, when combined with the high mass
ratio of adsorbed b2-m to immobilized antibody, a b2-
m adsorption site density can be achieved that is signif-
icantly greater than the highest reported to date (qs =
0.9 mg b2-m/mL settled gel [41]). This increase in the
b2m-adsorption site density should translate into a corre-
sponding decrease in the volume of adsorbent needed for
the proposed extracorporeal therapy, thereby improving
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the biocompatibility of the device. Future work for the
implementation of this technology will also include the
development of a comprehensive mathematical model
for b2-m clearance from ESRD patients. This model,
which should incorporate endogenous [56–59] and ex-
tracorporeal [44] b2-m mass transfer phenomena, would
give some insight into the long-term reduction rates that
could potentially be observed in patients.
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